Navigation Links
Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
Date:6/9/2008

PLYMOUTH MEETING, Pa., June 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) announced today a presentation by Genaera scientists of preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the 68th Scientific Sessions of the American Diabetes Association in San Francisco, California.

The poster presentation, entitled "Trodusquemine (MSI-1436) Improves Glucose Tolerance and HbA1C Levels in Murine Models of Insulin Resistance" concluded that treatment with MSI-1436 leads to significant improvements in insulin sensitivity as well as lower HbA1C levels and weight loss in animal models of diabetes. In one study, it was reported that four weekly treatments of MSI-1436 administered to ob/ob mice induced significant and dose-dependent reductions in HbA1C levels and body weight. In a separate study, treatment of db/db mice with a single dose of MSI-1436 demonstrated a significant improvement in oral glucose tolerance (OGTT) within 24 hours of dosing, and prior to any significant change in body weight. The scientists concluded that MSI-1436 may be useful for the treatment of type 2 diabetes and obesity in humans based on the marked improvements in insulin sensitivity, HbA1C, fasting blood glucose and body weight seen in these studies.

"All of our preclinical work continues to provide very encouraging support for our efforts to evaluate MSI-1436 as a therapy for both type 2 diabetes and obesity," stated Jack Armstrong, President and Chief Executive Officer of Genaera. "We have recently completed dosing in our second Phase 1a study of MSI-1436 in patients with type 2 diabetes and expect to initiate a planned Phase 1b (ascending multiple dose) stud
'/>"/>

SOURCE Genaera Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
2. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
3. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
4. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
5. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
6. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
7. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
8. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
9. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Atrium Medical Corporation Announces First Implant of First-in-Man CINATRA(TM) Voclosporin Coated Coronary Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ... systems especially for type 1 diabetes patients. ...
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014 /PRNewswire/ ... addressing the unmet needs of severely obese patients, ... study of beloranib, a selective inhibitor of methionine ... (PWS), a severe form of genetic obesity.  These ... and body composition, including reductions in body fat ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The ... offers Los Angeles a premier and ... laser and a $99 treatment special. Dr. Brandeis, focus is ... technology and offering expert medical advice to all patients. ... dramatic increase in the presence of tattoo regret and patients ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... JERUSALEM, Israel, June 15 ,The University of Pittsburgh ... announced today that the Institute has joined an elite,group of ... are now,enrolling patients to participate in the ExCell research study. ... assessing the safety and efficacy of StemEx(R), an,investigational product derived ...
... , IRVINE, Calif., June 12 Masimo (Nasdaq: ... Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that ... utility of Masimo PVI as a noninvasive and continuous ... this week at the European Society of Anaesthesiology (ESA) ...
Cached Medicine Technology:UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 2UPCI Joins ExCell Research Study Using Stem Cells for Leukemia and Lymphoma Patients 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... about multiple births dominating the media, it is easy to ... many couples trying to start a family. In fact, more ... number is growing. In the past 10 years the ... billion. Despite the troubled economy, reproductive medicine is thriving, ...
... Researchers from Thomas Jefferson University have identified a ... the growth and migration of prostate cancer cells, especially ... the American Journal of Pathology . , They ... the protein when compared to normal prostate cells, according ...
... socioeconomic characteristics of people who play state lotteries are similar ... with a small potential for high return, and just like ... invest this way in the stock market, research from The ... "Who Gambles in the Stock Market?" Alok Kumar, assistant professor ...
... Zuckerman, M.D., first considered a life in medicine at the ... weekly trials and tribulations of a young television doctor named ... show, it sparked an idea which led to an impressive ... Today, Dr. Zuckerman was named President of the American ...
... Healthcare Management Systems, Inc. (R) (HMS) ... Act of 2009 (ARRA) as it unfolds, ... the HIMSS informational webinar yesterday on ARRA, even with ... to wait to implement electronic health record (EHR) technology ...
... Consecutive Profitable Quarter Earns $.08 Per Diluted ShareLARGO, ... Bulletin Board: UVICF ; TSX Venture Exchange: ... specialty contact lenses, today reported its operating results ... (FY2009).Net sales, excluding royalty income, increased 1.2% to ...
Cached Medicine News:Health News:A Recession-Resistant Business? Introducing FertilityAuthority.com 2Health News:Proepithelin encourages cell growth and migration in prostate cancer 2Health News:Investors who 'gamble' in the stock market have same characteristics as lottery players 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 2Health News:Joseph D. Zuckerman, M.D., Elected President of the American Academy of Orthopaedic Surgeons 3Health News:HMS Responds to American Recovery and Reinvestment Act of 2009 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 2Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 3Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 4Health News:Unilens Vision Reports Record Second Quarter Revenue, and Royalty Income 5
Flexilog custom medical carts are configured to suite the requirements of FLEXILOG motility system users. With locking wheels and storage drawers, our carts are suitable for any care provider in any ...
... Calibration kit for convenient pH catheter calibration., ... to any procedure. The Alpine Calibration kit ... distilled water for your convenience. Simply cut ... your catheters to soak. No measuring or pouring! ...
Bravo Tubing/Filter Supplies (Ten tubing sets, ten filters)...
Bravo pH capsule with delivery system....
Medicine Products: